Reynolds Therapeutics is a pharmaceutical/Medical Device company focused on development of NeuroRelease a novel neurological drug delivery systems for post-operative pain. Founder Frank Reynolds develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Our lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models.
Looking for a particular Reynolds Therapeutics employee's phone or email?
The Reynolds Therapeutics annual revenue was $32.2 million in 2026.
1 people are employed at Reynolds Therapeutics.
Reynolds Therapeutics is based in Fort Myers, Florida.
The NAICS codes for Reynolds Therapeutics are [32, 32541, 3254, 325].
The SIC codes for Reynolds Therapeutics are [283, 2834, 28].